Eye drug Eylea has been recommended for approval in Europe for the treatment of macular oedema following central retinal vein occlusion (CRVO).
Manufacturer Bayer HealthCare said it had been recommended by the European Committee for Medicinal Products for Human Use, with a decision by the European Commission expected this year.
‘It is great news for patients in Europe suffering from CRVO, which is a debilitating disease affecting patients’ central vision,’ said Ian Pearce, consultant ophthalmologist at Royal Liverpool University Hospital. ‘I am hopeful that Eylea has the potential to provide me and my patients with a new treatment option.’
Eylea already has approval from NICE for the treatment of wet AMD (News 26.07.13).